Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Gamida Cell Ltd. GMDA
$1.95
-$0.12 (-6.27%)
На 18:01, 12 мая 2023
+258.97%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
214341610.00000000
-
week52high
3.66
-
week52low
0.56
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.58829200
-
EPS
-1.26000000
-
Last Dividend
0.00000000
-
Next Earnings Date
27 мар 2023 г. в 12:00
Описание компании
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 16 ноя 2021 г. |
| Needham | Buy | Buy | 16 ноя 2021 г. |
| Needham | Buy | Buy | 09 мар 2021 г. |
| Evercore ISI Group | Outperform | 01 июл 2020 г. | |
| Piper Sandler | Overweight | 26 мая 2020 г. | |
| Needham | Buy | Buy | 29 сент 2022 г. |
| Oppenheimer | Outperform | Outperform | 15 ноя 2022 г. |
| Needham | Buy | Buy | 22 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| WILLS STEPHEN T | A | 9500 | 9500 | 18 ноя 2022 г. |
| WILLS STEPHEN T | A | 13677 | 2000 | 18 ноя 2022 г. |
| MOCH KENNETH I | A | 9500 | 9500 | 18 ноя 2022 г. |
| MOCH KENNETH I | A | 4000 | 2000 | 18 ноя 2022 г. |
| Tomasello Shawn | A | 9500 | 9500 | 18 ноя 2022 г. |
| Tomasello Shawn | A | 13677 | 2000 | 18 ноя 2022 г. |
| ADAMS JULIAN | A | 9500 | 9500 | 18 ноя 2022 г. |
| ADAMS JULIAN | A | 195450 | 2000 | 18 ноя 2022 г. |
| Blum Robert I | A | 12500 | 12500 | 18 ноя 2022 г. |
| Blum Robert I | A | 54000 | 2000 | 18 ноя 2022 г. |
Новостная лента
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
Business Wire
11 мая 2023 г. в 17:20
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conferenc.
Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today
PennyStocks
10 мая 2023 г. в 12:47
Penny stocks with unusual options activity today The post Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Gamida Cell (GMDA) Stock Down 19% Today?
InvestorPlace
19 апр 2023 г. в 09:01
Gamida Cell (NASDAQ: GMDA ) stock is falling on Wednesday after the cell therapy company revealed details of a public securities offering. According to a press release from the company, it is selling both shares of GMDA stock, as well as warrants to purchase shares of its stock.
Gamida Cell Stock Jumps Over 100% on FDA Approval
MarketBeat
18 апр 2023 г. в 13:10
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight blood cancer and other illnesses.
Gamida Cell shares jump on FDA recognition of allogeneic cell therapy
Proactive Investors
18 апр 2023 г. в 12:13
Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug candidate Omisirge received breakthrough therapy designation, priority review and orphan drug designation from the FDA, sending shares of the Boston-based company nearly 45% higher in midday trading.